NCT04265027View on ClinicalTrials.gov

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

July 24, 2018

Study Completion Date

July 24, 2018

Conditions

Parkinson Disease

Interventions

DRUG

50 mg BIA 9 1067

Hard Capsule; Oral

DRUG

25 mg BIA9 1067

Hard Capsule; Oral

DRUG

50 mg Ongentys

Hard Capsule; Oral

DRUG

25 mg Ongentys

Hard Capsule; Oral

Trial Locations (1)

CF48 4DR

Simbec Research Ltd, Merthyr Tydfil

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT04265027 - Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC) | Biotech Hunter | Biotech Hunter